肝がん診断の世界市場：市場規模・シェア・動向分析 (検査の種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

肝がん診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の肝がん診断の市場規模は2025年から2030年にかけてCAGR 6.67%を記録し、2030年には146億7,632万米ドルに達すると推定されています。

肝臓がんの有病率の増加、診断のための技術の進歩、治療と生存率のためのスクリーニングの重要性に対する認識が、肝がん診断の市場成長を促進しています。

米国がん学会の統計によると、2022年には約4万1,260人が新たに肝臓がんと診断されると予想されています。また、2020年のGlobocanの発表によると、世界中で約83万180人が肝臓がんにより死亡しています。WHOはまた、慢性肝炎ウイルス感染が人口に蔓延しており、C型肝炎ウイルス（HCV）は約5,800万人が罹患していると推定しています。HCVとB型肝炎ウイルス（HBV）は、肝がんの最も一般的な危険因子です。加えて、肝硬変や喫煙といった他の危険因子への感染や曝露は、生存率を高めるための肝臓がんの早期治療・診断のためのスクリーニング・ソリューションの需要を急増させると思われます。そのため、診断薬製品に対する需要は予測期間中に高まり、市場の成長を促進します。

COVID-19パンデミックは肝がん患者の治療を中断させ、死亡率の上昇をもたらしました。スクリーニングや処置の遅れや中断は、この病気の患者に影響を与えました。例えば、2021年6月の論文では、欧州諸国の研究者が、パンデミックが肝臓がん患者の日常診療に与えた影響を評価し、その修正によって治療成績が大きく変化したと結論付けています。しかし、技術の進歩やCOVID-19時の免疫系に対する理解が深まったことで、多くの新しいヘルスケア診断薬が発売されました。さらに、パンデミックは健康の重要性を高め、早期診断・治療のための定期的な健康診断へと人々を押し上げました。

診断の技術的進歩は、世界中の多くの官民組織による意識の向上と支援的イニシアチブの結果です。この結果、様々ながんの検診や診断が促進され、診断ソリューションの成長が期待されます。例えば、2022年9月、米国の診断薬企業であるDelfi Diagnostics, Inc.は、欧州における大規模スクリーニング試験においてリキッドバイオプシーのパートナーに選ばれたと発表しました。

肝がんの早期発見のための革新的なソリューションに対する需要の増加に対応するため、複数の企業が新製品を発売しています。例えば、2020年3月、F.ホフマン・ラ・ロシュ社は、「ブレークスルー・デバイス」賞を受賞した。ロシュは、新しいElecsys GALADスコアで米国FDAから「Breakthrough Device Designation」を受けた。このスコアは、臨床医にタイムリーで正確な情報を提供することで、肝細胞がん（HCC）の診断をサポートします。主な企業は、新製品開発のための共同研究、契約、提携も進めています。このような製品開発や市場開拓は市場競争を激化させ、肝がん診断市場の成長を促進します。

肝がん診断市場：分析概要

• 検査の種類別では、正確かつ費用対効果の高い病期診断に対する需要の高まりにより、臨床検査が2024年に最大のシェアを占めました。さらに、治療計画に対する反応をモニタリングするための臨床検査の応用も成長を後押ししています。
• 最終用途別では、病院・診断検査室のセグメントが2024年の市場を独占しました。医療専門家の助けを借りて診断と治療を行う一次治療センターとして、これらの環境が好まれることが、このセグメントの成長を後押ししています。
• 北米が2024年に最も高いシェアを占めたのは、人口における危険因子の蔓延によるものです。これは、この地域における疾病スクリーニングに対する意識の高まりと先進技術の採用が成長を牽引しているためです。
• アジア太平洋地域は、予測期間中に最も速いCAGRを示すでしょう。さらに、新興経済諸国は、同地域の新興国における診断検査の採用を後押しします。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 肝がん診断市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 肝がん診断市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 肝がん診断市場：検査の種類別の推定・動向分析

• セグメントダッシュボード
• 肝がん診断市場：変動分析、検査の種類別
• 肝がん診断の市場規模と動向分析：検査の種類別（2018～2030年）
  • 世界の臨床検査市場（2018～2030年）
  • 画像診断
  • 内視鏡検査
  • 生検

第5章 肝がん診断市場：最終用途別の推定・動向分析

• 市場シェア：最終用途別（2024年・2030年）
• セグメントダッシュボード
• 世界の肝がん診断市場：最終用途別の展望
• 市場規模の予測と動向分析（2018～2030年）
• 病院・診断検査室
  • 世界の病院・診断検査室市場（2018～2030年）
• 学術調査機関
  • 世界の学術研究機関市場（2018～2030年）
• 製薬・CRO検査室
  • 世界の製薬・CRO検査室市場（2018～2030年）

第6章 肝がん診断市場：地域別の推定・動向分析

• 市場シェア分析：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 北米：SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州：SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋：SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ：SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 最新動向と影響分析：主要メーカー別
• 企業/競合の分類
• ベンダー情勢
  • 主要な流通業者・チャネルパートナーの一覧
  • 主要顧客
  • 主要企業の市場シェア分析 (2024年)
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Qiagen NV
  • Siemens Healthineers
  • Becton, Dickinson &Company
  • Illumina, Inc.
  • Epigenomics AG
  • Koninklijke Philips NV
  • Fujifilm Medical Systems USA, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 4 North America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 5 U.S Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 6 U.S Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 7 Canada Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 8 Canada Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 9 Mexico Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 10 Mexico Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 11 Europe Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 12 Europe Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 13 UK Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 14 UK Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 15 Germany Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 16 Germany Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 17 France Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 18 France Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 19 Italy Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 20 Italy Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 21 Spain Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 22 Spain Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 23 Denmark Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 24 Denmark Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 25 Sweden Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 26 Sweden Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 27 Norway Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 28 Norway Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 31 Japan Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 32 Japan Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 33 China Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 34 China Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 35 India Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 36 India Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 37 Australia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 38 Australia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 39 South Korea Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 40 South Korea Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 41 Thailand Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 42 Thailand Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 43 Latin America Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 44 Latin America Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 45 Brazil Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 46 Brazil Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 47 Argentina Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 48 Argentina Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 49 MEA Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 50 MEA Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 51 South Africa Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 52 South Africa Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 53 Saudi Arabia Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 54 Saudi Arabia Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 55 UAE Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 56 UAE Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)
• Table 57 Kuwait Liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 58 Kuwait Liver cancer diagnostics market, by end user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Liver cancer diagnostics market: market outlook
• Fig. 14 Liver cancer diagnostics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Liver cancer diagnostics market driver impact
• Fig. 20 Liver cancer diagnostics market restraint impact
• Fig. 21 Liver cancer diagnostics market strategic initiatives analysis
• Fig. 22 Liver cancer diagnostics market: Test type movement analysis
• Fig. 23 Liver cancer diagnostics market: Test type outlook and key takeaways
• Fig. 24 Laboratory Tests Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
• Fig. 25 Imaging Liver Cancer Diagnostics estimates and forecast, 2018 - 2030
• Fig. 26 Endoscopy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
• Fig. 27 Biopsy Liver Cancer Diagnostics market estimates and forecast, 2018 - 2030
• Fig. 28 Liver cancer diagnostics market: End-use movement analysis
• Fig. 29 Liver cancer diagnostics market: End-use outlook and key takeaways
• Fig. 30 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030
• Fig. 31 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
• Fig. 32 Pharmaceutical & CRO Laboratories market estimates and forecasts, 2018 - 2030
• Fig. 33 Global Liver cancer diagnostics market: Regional movement analysis
• Fig. 34 Global Liver cancer diagnostics market: Regional outlook and key takeaways
• Fig. 35 Global Liver cancer diagnostics market share and leading players
• Fig. 36 North America market share and leading players
• Fig. 37 Europe market share and leading players
• Fig. 38 Asia Pacific market share and leading players
• Fig. 39 Latin America market share and leading players
• Fig. 40 Middle East & Africa market share and leading players
• Fig. 41 North America: SWOT
• Fig. 42 Europe SWOT
• Fig. 43 Asia Pacific SWOT
• Fig. 44 Latin America SWOT
• Fig. 45 MEA SWOT
• Fig. 46 North America, by country
• Fig. 47 North America
• Fig. 48 North America market estimates and forecasts, 2018 - 2030
• Fig. 49 U.S.
• Fig. 50 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 51 Canada
• Fig. 52 Canada market estimates and forecasts, 2018 - 2030
• Fig. 53 Mexico
• Fig. 54 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 55 Europe
• Fig. 56 Europe market estimates and forecasts, 2018 - 2030
• Fig. 57 UK
• Fig. 58 UK market estimates and forecasts, 2018 - 2030
• Fig. 59 Germany
• Fig. 60 Germany market estimates and forecasts, 2018 - 2030
• Fig. 61 France
• Fig. 62 France market estimates and forecasts, 2018 - 2030
• Fig. 63 Italy
• Fig. 64 Italy market estimates and forecasts, 2018 - 2030
• Fig. 65 Spain
• Fig. 66 Spain market estimates and forecasts, 2018 - 2030
• Fig. 67 Denmark
• Fig. 68 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 69 Sweden
• Fig. 70 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 71 Norway
• Fig. 72 Norway market estimates and forecasts, 2018 - 2030
• Fig. 73 Asia Pacific
• Fig. 74 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 75 China
• Fig. 76 China market estimates and forecasts, 2018 - 2030
• Fig. 77 Japan
• Fig. 78 Japan market estimates and forecasts, 2018 - 2030
• Fig. 79 India
• Fig. 80 India market estimates and forecasts, 2018 - 2030
• Fig. 81 Thailand
• Fig. 82 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 83 South Korea
• Fig. 84 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 85 Australia
• Fig. 86 Australia market estimates and forecasts, 2018 - 2030
• Fig. 87 Latin America
• Fig. 88 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 89 Brazil
• Fig. 90 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 91 Argentina
• Fig. 92 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 93 Middle East and Africa
• Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 95 South Africa
• Fig. 96 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 97 Saudi Arabia
• Fig. 98 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 99 UAE
• Fig. 100 UAE market estimates and forecasts, 2018 - 2030
• Fig. 101 Kuwait
• Fig. 102 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 103 Market share of key market players- Liver cancer diagnostics market

Liver Cancer Diagnostics Market Growth & Trends:

The global liver cancer diagnostics market size is estimated to reach USD 14,676.32 million by 2030, registering a CAGR of 6.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic's impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the 'Breakthrough Device Designation' from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights:

• On the basis of test type, laboratory tests held the largest share in 2024, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
• Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2024. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment's growth
• North America accounted for the highest share in 2024, due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
• Asia Pacific will exhibit the fastest CAGR during the forecast period, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region's emerging countries.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test type
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test type outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Incidence of Liver Cancer
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic imaging
• 3.3. Liver Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
• 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2018 to 2030 (USD Million)
  • 4.3.1. Global Laboratory Tests Market, 2018 - 2030 (USD Million)
    • 4.3.1.1. Biomarkers
      • 4.3.1.1.1. Global biomarkers market, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
          • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.2. Enzymes and Isoenzymes
          • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.3. Growth Factors and Receptors
          • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.4. Molecular Markers
          • 4.3.1.1.1.4.1. Global molecular markers market, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.5. Pathological Biomarkers
          • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2018 - 2030 (USD Million)
    • 4.3.1.2. Blood Tests
      • 4.3.1.2.1. Global blood tests market, 2018 - 2030 (USD Million)
  • 4.3.2. Imaging
    • 4.3.2.1. Global Imaging Market, 2018 - 2030 (USD Million)
  • 4.3.3. Endoscopy
    • 4.3.3.1. Global Endoscopy Market, 2018 - 2030 (USD Million)
  • 4.3.4. Biopsy
    • 4.3.4.1. Global Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Hospitals & Diagnostic Laboratories
  • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2018 - 2030 (USD Million)
• 5.6. Academic & Research Institutes
  • 5.6.1. Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 5.7. Pharmaceutical & CRO Laboratories
  • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. North America: SWOT Analysis
  • 6.5.2. U.S.
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/Reimbursement
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/Reimbursement
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/Reimbursement
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe: SWOT Analysis
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/Reimbursement
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/Reimbursement
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/Reimbursement
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/Reimbursement
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/Reimbursement
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/Reimbursement
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/Reimbursement
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework/Reimbursement
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific: SWOT Analysis
  • 6.7.2. Japan
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/Reimbursement
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/Reimbursement
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/Reimbursement
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Australia
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/Reimbursement
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. South Korea
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/Reimbursement
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework/Reimbursement
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America: SWOT Analysis
  • 6.8.2. Brazil
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/Reimbursement
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/Reimbursement
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. MEA: SWOT Analysis
  • 6.9.2. South Africa
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/Reimbursement
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/Reimbursement
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/Reimbursement
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. Abbott Laboratories
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Services benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Thermo Fisher Scientific, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Services benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. F. Hoffmann-La Roche Ltd.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Services benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Qiagen N.V.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Services benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Siemens Healthineers
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Services benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Becton, Dickinson & Company
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Services benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Illumina, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Services benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Epigenomics AG
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Services benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Koninklijke Philips N.V.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Services benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Services benchmarking
    • 7.3.13.4. Strategic initiatives